secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0000950170-24-123340
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta Q3 net loss $28.3M; cash $405.3M; drops NHL, focuses NKX019 on autoimmune
--------------------------------------------------------------------------------

- Net loss of $28.3M ($0.39 per basic/diluted share) for Q3 2024; cash, equivalents, investments $405.3M.
- First patient dosed in Ntrust-1 (lupus nephritis) and CUIMC IST (SLE); enrollment ongoing.
- Ntrust-2 (systemic sclerosis, myositis, vasculitis) enrollment expected by year-end 2024; preliminary data in 2025.
- Forgoes further NKX019 development in non-Hodgkin lymphoma; no new NHL trials planned.
- Current cash expected to fund operations into late 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024123340/0000950170-24-123340-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024123340/nktx-20241107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-123340

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer